AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $48.75.

A number of equities research analysts recently weighed in on ANAB shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. Wedbush reiterated an “outperform” rating and set a $45.00 price objective on shares of AnaptysBio in a research note on Tuesday, September 30th. HC Wainwright boosted their price objective on shares of AnaptysBio from $38.00 to $59.00 and gave the stock a “buy” rating in a research note on Tuesday, September 30th. JPMorgan Chase & Co. boosted their price objective on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Finally, UBS Group reiterated a “neutral” rating and set a $20.00 price objective (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th.

AnaptysBio Price Performance

Shares of ANAB opened at $31.37 on Wednesday. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $36.54. The company has a 50-day moving average of $22.98 and a 200 day moving average of $22.35. The firm has a market capitalization of $878.27 million, a price-to-earnings ratio of -7.00 and a beta of -0.18.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The company had revenue of $22.26 million during the quarter, compared to analyst estimates of $11.55 million. On average, equities analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. First Light Asset Management LLC raised its stake in shares of AnaptysBio by 433.3% during the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock worth $86,139,000 after acquiring an additional 3,764,720 shares in the last quarter. Palo Alto Investors LP grew its position in AnaptysBio by 20.9% during the 1st quarter. Palo Alto Investors LP now owns 1,020,713 shares of the biotechnology company’s stock worth $18,975,000 after purchasing an additional 176,742 shares during the last quarter. Assenagon Asset Management S.A. grew its position in AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after purchasing an additional 822,975 shares during the last quarter. Woodline Partners LP grew its position in AnaptysBio by 63.1% during the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after purchasing an additional 305,950 shares during the last quarter. Finally, 683 Capital Management LLC grew its position in AnaptysBio by 155.6% during the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after purchasing an additional 304,373 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.